JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms

Christina Schjellerup Eickhardt-Dalbøge*, Henrik V Nielsen, Kurt Fuursted, Christen Rune Stensvold, Lee O' Brien Andersen, Berit Lilje, Morten Kranker Larsen, Lasse Kjaer, Sarah Friis Christensen, Trine Alma Knudsen, Vibe Skov, Anders Lindholm Sørensen, Christina Ellervik, Lars Rønn Olsen, Jens Jørgen Elmer Christensen, Xiaohui Chen Nielsen, Hans Carl Hasselbalch, Anna Cäcilia Ingham

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

BACKGROUND: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis.

METHODS: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation.

RESULTS: MPN patients had a higher observed richness (median, 245 [range, 49-659]) compared with HCs (191.5 [range, 111-300; p = .003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p < .001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation.

CONCLUSION: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.

OriginalsprogEngelsk
Antal sider12
TidsskriftEuropean Journal of Haematology
DOI
StatusUdgivet, E-publikation før trykning - 16 jan. 2024

Bibliografisk note

© 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.

Fingeraftryk

Udforsk hvilke forskningsemner 'JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms' indeholder.

Citationsformater